Icure Pharmaceutical Incorporation (175250) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Icure Pharmaceutical Incorporation (175250) has a cash flow conversion efficiency ratio of -0.055x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-3.28 Billion ≈ $-2.23 Million USD) by net assets (₩59.43 Billion ≈ $40.27 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Icure Pharmaceutical Incorporation stock valuation for the company's overall valuation and market capitalisation.
Icure Pharmaceutical Incorporation - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Icure Pharmaceutical Incorporation's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Icure Pharmaceutical Incorporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Icure Pharmaceutical Incorporation ranked by their cash flow conversion efficiency. Explore 175250 operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
EM-Tech.CO. LTD
KQ:091120
|
-0.060x |
|
American Creek Resources Ltd
V:AMK
|
-0.114x |
|
Aptech Limited
NSE:APTECHT
|
0.008x |
|
Shandong Chenming Paper Holdings Ltd Class B
SHE:200488
|
-0.032x |
|
Bangkok Ranch PCL
BK:BR
|
0.033x |
|
ALT Telecom Public Company Limited
BK:ALT
|
-0.053x |
|
CanAlaska Uranium Ltd
V:CVV
|
-0.078x |
|
Aurea SA
PA:AURE
|
0.050x |
Annual Cash Flow Conversion Efficiency for Icure Pharmaceutical Incorporation (2015–2024)
The table below shows the annual cash flow conversion efficiency of Icure Pharmaceutical Incorporation from 2015 to 2024. View Icure Pharmaceutical Incorporation (175250) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩60.26 Billion ≈ $40.84 Million |
₩-17.05 Billion ≈ $-11.56 Million |
-0.283x | -24.75% |
| 2023-12-31 | ₩59.59 Billion ≈ $40.39 Million |
₩-13.52 Billion ≈ $-9.16 Million |
-0.227x | -80.30% |
| 2022-12-31 | ₩89.67 Billion ≈ $60.77 Million |
₩-11.28 Billion ≈ $-7.65 Million |
-0.126x | +54.07% |
| 2021-12-31 | ₩95.76 Billion ≈ $64.89 Million |
₩-26.23 Billion ≈ $-17.77 Million |
-0.274x | -147.68% |
| 2020-12-31 | ₩112.15 Billion ≈ $76.01 Million |
₩-12.40 Billion ≈ $-8.41 Million |
-0.111x | -81.49% |
| 2019-12-31 | ₩97.53 Billion ≈ $66.10 Million |
₩-5.94 Billion ≈ $-4.03 Million |
-0.061x | +29.34% |
| 2018-12-31 | ₩84.69 Billion ≈ $57.40 Million |
₩-7.30 Billion ≈ $-4.95 Million |
-0.086x | -234.63% |
| 2017-12-31 | ₩17.47 Billion ≈ $11.84 Million |
₩1.12 Billion ≈ $758.55K |
0.064x | +122.24% |
| 2016-12-31 | ₩16.94 Billion ≈ $11.48 Million |
₩-4.88 Billion ≈ $-3.31 Million |
-0.288x | -741.49% |
| 2015-12-31 | ₩5.96 Billion ≈ $4.04 Million |
₩-204.05 Million ≈ $-138.28K |
-0.034x | -- |
About Icure Pharmaceutical Incorporation
Icure Pharmaceutical Incorporation, a biopharmaceutical company, researches, develops, and sells pharmaceutical and cosmetic products in South Korea. The company offers functional, nature-derived, derma, and customized cosmetics products. It also offers eye gel, hydro nude gel, lip gel mask, and functional patch products; and sheet, mud, foil, and melting masks. In addition, the company provides … Read more